Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd
CN
News trends
Position:
Homepage
/
/
/
Dongfang Baitai PD-1 Project won the Excellent Award of Beijing Tianjin Hebei Collaborative Innovation
Check category

Dongfang Baitai PD-1 Project won the Excellent Award of Beijing Tianjin Hebei Collaborative Innovation

  • Categories:Company News
  • Author:
  • Origin:东方百泰
  • Time of issue:2022-05-23
  • Views:322

(Summary description)In May 2017, the Beijing Tianjin Hebei Collaborative Innovation Award Selection and Award Ceremony of the 11th Beijing Invention and Innovation Competition was held in Beijing Guangda Building. During the meeting, the special prize for the coordinated development of Beijing, Tianjin and Hebei in the 11th Beijing Invention and Innovation Competition was reviewed on the spot. All the awards were announced and awarded. The entry project of Beijing Dongfang Baitai Biotechnology Co., Ltd.: a monoclonal antibody against PD-1 and its winning method won the Beijing Tianjin Hebei Collaborative Innovation Excellence Award.

Dongfang Baitai PD-1 Project won the Excellent Award of Beijing Tianjin Hebei Collaborative Innovation

(Summary description)In May 2017, the Beijing Tianjin Hebei Collaborative Innovation Award Selection and Award Ceremony of the 11th Beijing Invention and Innovation Competition was held in Beijing Guangda Building. During the meeting, the special prize for the coordinated development of Beijing, Tianjin and Hebei in the 11th Beijing Invention and Innovation Competition was reviewed on the spot. All the awards were announced and awarded. The entry project of Beijing Dongfang Baitai Biotechnology Co., Ltd.: a monoclonal antibody against PD-1 and its winning method won the Beijing Tianjin Hebei Collaborative Innovation Excellence Award.

  • Categories:Company News
  • Author:
  • Origin:东方百泰
  • Time of issue:2022-05-23
  • Views:322
Information

In May 2017, the Beijing Tianjin Hebei Collaborative Innovation Award Selection and Award Ceremony of the 11th Beijing Invention and Innovation Competition was held in Beijing Guangda Building. During the meeting, the special prize for the coordinated development of Beijing, Tianjin and Hebei in the 11th Beijing Invention and Innovation Competition was reviewed on the spot. All the awards were announced and awarded. The entry project of Beijing Dongfang Baitai Biotechnology Co., Ltd.: a monoclonal antibody against PD-1 and its winning method won the Beijing Tianjin Hebei Collaborative Innovation Excellence Award.

 

 

The Beijing Invention and Innovation Competition was hosted by Zhongguancun Social Organization Federation and hosted by Beijing Invention Association. Since 2014, the important strategy of coordinated development of Beijing, Tianjin and Hebei has been put forward. In the past three years, a magnificent movement of coordinated development of Beijing, Tianjin and Hebei has been played in China. The coordinated development of Beijing, Tianjin and Hebei is fundamentally driven by innovation and scientific and technological innovation, which is a key measure that affects the new driving force for economic development, new impetus for industrial upgrading and new space for high-end talents and technology in the three regions. The innovation of the biomedical industry has been included in the key areas of coordinated development.

Monoclonal antibody drugs are the most difficult and the highest level in biological medicine. It is also the largest area of the market. It is the leading force to promote the development of the biomedical industry. Its development level has become an important symbol to measure the overall level of a country's biomedical development.

Dongfang Baitai screened a whole human monoclonal antibody drug JY034 project with high affinity against Programmed Cell Death 1 (PD-1) through phage library display technology. Through the independent innovation and research and development of PD-1 monoclonal antibody drugs, Dongfang Baitai has built a leading level monoclonal antibody drug research and development platform with China's independent intellectual property rights. We have broken through many technical bottlenecks that limit the rapid development of China's antibody drug industry. The company cultivates and sets up a leading technical team for antibody drug research and industrial transformation to promote the leapfrog development of China's antibody industry. JY034 has obtained the Chinese invention patent authorization and applied through PCT. It has entered 18 countries or regions in Europe, Eurasia, the United States, Japan, South Korea, Canada, etc. It is currently in the preclinical development stage.

Several clinical studies have confirmed that PD-1 monoclonal antibody therapy can significantly improve the survival benefits of more than 10 kinds of cancer patients, including lung cancer, kidney cancer, melanoma, lymph cancer, head and neck cancer, bladder cancer, triple negative breast cancer, liver cancer, stomach cancer, esophageal cancer, colon cancer, glioma cancer, etc. Due to the remarkable efficacy of PD-1 monoclonal antibody in cancer immunotherapy, it deserves to be the most dazzling star drug in the field of cancer therapy.

Many multinational companies compete to develop monoclonal antibody against PD-1. Among them, Pembrolizumab of MSD, the leader, and Nivolumab of Bristol Myers Squibb were approved by the US FDA for listing in September and December 2014 respectively. The approved indications are melanoma and non-small cell lung cancer. The late stage indications are extended to more than 30 types of cancers, such as advanced renal cell carcinoma, colon cancer and gastric cancer. It shows good safety and lasting tumor remission effect in clinic. It has broad clinical application prospects.

At present, there is no similar drug on the market in China. JY034 has a good effect in vitro. The development of this drug can not only fill the clinical needs of similar drugs in China. It is also possible to improve the survival of patients better than similar products. It has good value of drug development and application.

The PD-1 monoclonal antibody independently developed by Dongfang Baitai will drive the innovation ability of China's antibody industry. The successful transformation of research results will give many cancer patients in China the opportunity and ability to use antibody drugs. At the same time, it also allows domestic monoclonal antibody drugs to go abroad, participate in international competition, and create a national brand of antibodies.

The acquisition of many honors shows the innovative strength of Dongfang Baitai in the field of biomedical monoclonal antibody. The innovative R&D platform is in line with international standards, and the innovative R&D system has been constantly improved, which will bring lasting confidence to the team of Dongfang Baitai. We will continue to rely on scientific and technological innovation to improve the enterprise's independent R&D and industrialization capacity of antibody drugs, accelerate the emergence of a series of innovative monoclonal antibody drugs, and rapidly improve the overall level and international competitiveness of China's antibody industry!

Scan the QR code to read on your phone

推荐新闻

Follow us

1

Follow the official WeChat official account

Or search "Oriental Baitai"

More exciting waiting for you!

Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com

Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd    SEO    京ICP备********号 

Beijing Dongfang Baitai Biotechnology Co., Ltd

Online customer service
Customer service hotline
010-51571019 010-51571019
Service time:
8:30 - 17:30
Customer service group:
在线客服